On Wednesday, September 9, 2026, Blau Farmacêutica (BLAU3) reported that the Executive Board of B3 approved the automatic extension of the deadline for the Company to comply with the minimum percentage of shares in circulation in the market (free float, shares in circulation) from December 31, 2026 to December 31, 2027, considering the original compliance deadline and the macroeconomic scenario.

Advertisement

📊 Is BLAU3 worth investing in?

BLAU3Blau Farmacêutica
15+ years of data
PriceR$ 12.33
Dividend Yield6.06 %
P/L12.30
P/VPA1.23
View full analysis of BLAU3
Tags:
Blau FarmacêuticaBLAU3